TSO (Details Textual)
|
6 Months Ended | 72 Months Ended | 0 Months Ended | 3 Months Ended | 6 Months Ended | 12 Months Ended | 1 Months Ended | 3 Months Ended | 6 Months Ended | 0 Months Ended | 6 Months Ended | 12 Months Ended | ||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2011
USD ($)
|
Jun. 30, 2012
USD ($)
|
Dec. 31, 2011
USD ($)
|
Jan. 07, 2011
Ova Med [Member]
USD ($)
|
Mar. 31, 2012
Ova Med [Member]
USD ($)
|
Jun. 30, 2012
Ova Med [Member]
USD ($)
|
Dec. 31, 2011
Ova Med [Member]
USD ($)
|
Apr. 30, 2012
Falk [Member]
USD ($)
|
Apr. 30, 2012
Falk [Member]
EUR (€)
|
Mar. 31, 2012
Falk [Member]
USD ($)
|
Mar. 31, 2012
Falk [Member]
EUR (€)
|
Jun. 30, 2012
Falk [Member]
USD ($)
|
Jun. 30, 2012
Falk [Member]
EUR (€)
|
Jan. 07, 2011
Asphelia Asset Purchase [Member]
USD ($)
|
Jun. 30, 2012
Asphelia Asset Purchase [Member]
|
Dec. 31, 2011
Asphelia Asset Purchase [Member]
USD ($)
|
|
TSO (Textual) [Abstract] | ||||||||||||||||
Date of acquisition | Jan. 07, 2011 | |||||||||||||||
Payment for purchase of assets | $ 20,706,000 | |||||||||||||||
Number of Series B Convertible Preferred Stock issued | 2,525,677 | |||||||||||||||
Series B Convertible Preferred Stock issued, per share | $ 6.38 | |||||||||||||||
PCP Note, principal amount | 750,000 | |||||||||||||||
Cash paid for asset purchase | 3,809,000 | |||||||||||||||
Payment to related party | 3,400,000 | 61,000,000 | ||||||||||||||
Repayment of Asphelia's debt | 400,000 | |||||||||||||||
Acquired in-process research and development | 20,706,000 | 20,706,000 | 20,700,000 | |||||||||||||
Contingent milestone payments to OvaMed | 5,400,000 | |||||||||||||||
Milestone payments to related party | 200,000,000 | 1,500,000 | 1,400,000 | 1,000,000 | ||||||||||||
Current expiry date of Supply Agreement | 2014-03 | |||||||||||||||
Automatic renewal of OvaMed Supply Agreement | 1 year | |||||||||||||||
Prior notice period for non renewal of OvaMed Supply Agreement | 12 months | |||||||||||||||
Cash paid to Falk | 6,500,000 | 5,000,000 | ||||||||||||||
Royalty payable to Falk | 1.00% | 1.00% | ||||||||||||||
Additional payments to Falk | 2,000,000 | 1,500,000 | ||||||||||||||
Remaining amount payable to Falk | 3,300,000 | 2,500,000 | ||||||||||||||
Accrued Milestones | $ 3,154,000 | $ 2,899,000 | ||||||||||||||
Percentage responsibility for clinical testing | 50.00% | 50.00% |